Eli Lilly shares (NYSE:LLY) added 3.76% this past week, closing out the month of May with a gain of 18.23%, and above the $1,100 level at $1,105. This latest week saw the US pharma giant announce plans to acquire three vaccine developers in deals worth up to $3.8 billion combined. The three companies (Curevo, LimmaTech Biologics, and Vaccine Company) represent a deeper push by Lilly into infectious disease prevention, a sector the drugmaker has been building out alongside its established obesity and diabetes franchises.
The acquisitions mark a continuation of Lilly’s recent deal activity, which has accelerated in 2026 and now exceeds levels seen in previous years. According to the company, the transactions align with its strategy of investing in differentiated technology platforms aimed at addressing major health challenges.
Lilly noted that infectious diseases remain a significant cause of global morbidity, both through immediate illness and the longer-term health effects that can follow an infection. The company said it has spent 150 years developing medicines to address some of the world’s most pressing health problems, and the latest moves extend that mission into prevention as well as treatment.
Why does it matter?
While Eli Lilly is a US-listed stock, the deal carries implications for Australian investors tracking global pharmaceutical and biotech trends, particularly those exposed to the sector through ASX-listed healthcare names.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The acquisition spree signals that large-cap pharmaceutical companies are willing to deploy significant capital on bolt-on deals, even in a market environment where inflation concerns and higher interest rates have dampened some M&A activity. That willingness to spend can lift sentiment across the biotech sector, particularly for smaller developers with promising pipelines or technology platforms that could attract interest from larger players.
Lilly’s move into vaccines is driven by strong cash flow from its obesity drug franchise, which has been a major growth driver. The company’s ability to use those earnings to fund strategic acquisitions demonstrates how a single blockbuster product category can support broader portfolio diversification.
The $1Trillion Club
Eli Lilly has been one of the standout performers in global pharmaceutical markets over the past few years, driven largely by the success of its obesity drugs. The strong cash flow from that franchise has given the company significant financial flexibility to pursue acquisitions and expand into adjacent therapeutic areas.
Such has been the rate of ascent, with LLY shares adding 50% over the past year, that the company is now one of few who can say they fall into the $1trillion market cap club. There have been a few additions in recent weeks from tech, but none that have made the move from the pharma sector, highlighting the strength of the franchise.
The company’s 2026 deal activity has already surpassed prior years, according to the announcement, and the latest vaccine-focused acquisitions fit within a broader strategy of investing in differentiated technology platforms. Lilly has not disclosed the exact breakdown of the $3.8 billion total across the three deals, but the combined figure suggests a meaningful commitment to building out its infectious disease capabilities.
The move into vaccines also reflects a broader industry trend. Since the pandemic, several large pharmaceutical companies have been re-evaluating their infectious disease portfolios, both to capture commercial opportunities and to strengthen their capabilities in outbreak response and prevention.
Lilly’s decision to acquire three separate vaccine developers rather than building those capabilities in-house suggests a preference for speed and proven technology over slower internal development timelines. For a company with Lilly’s financial resources, external acquisition can be a faster route to market than multi-year internal R&D programs, particularly in areas where the company lacks established expertise.
The broader pharmaceutical sector has seen a pickup in M&A activity in 2026, driven in part by companies seeking to diversify revenue streams and offset patent cliffs on older blockbuster drugs. Lilly’s aggressive deal pace this year fits that pattern, and may encourage other large-cap pharmaceutical companies to follow suit if they see strategic value in bolt-on acquisitions.
